chartexchange

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results

GlobeNewswire Inc. | Nov 4, 2026 4:01 PM EST

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)

Read original article